Compared with the control group, statistical analysis showed that anti-EGFR targeted agents with chemotherapy increased the incidence of some AEs in patients, such as diarrhea (RR: 1.71), fatigue (RR: 1.54), rash (RR: 26.60), skin reactions (RR: 44.52), hemoglobin (RR: 2.43), hypermagnesemia (RR: 13.10), stomatitis (RR: 2.90), cardiac events (RR: 29.62), and infusion-related reactions (RR: 2.32). Here, EGFR is linked to Hypermagnesemia.